Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis announced its participation in the BMO Capital Markets 16th Annual Farm to Market Virtual Conference, scheduled for May 19 and 20, 2021. The company's CEO, Miguel Martin, and CFO, Glen Ibbott, will hold virtual one-on-one meetings with investors during the conference. Aurora is a leading player in the cannabis industry, with a diverse brand portfolio that serves both medical and consumer markets. Its shares are traded on both the NYSE and TSX under the symbol ACB.
Aurora Cannabis reported Q3 2021 net revenue of $55.2 million, a decrease of 20.8% year-over-year, primarily due to a 53% drop in consumer cannabis sales impacted by COVID-19 challenges. Medical cannabis revenue rose 17% to $36.4 million, supported by international sales growth of 134%. The company plans $60-$80 million in additional annual cost savings, building on previous reductions of $300 million. Aurora retains a robust cash position with approximately $525 million available, enabling investment in organic growth and potential U.S. acquisitions.
Aurora Cannabis Inc. (ACB) will hold a conference call on May 13, 2021, at 5:00 p.m. Eastern Time to discuss its third-quarter fiscal year 2021 results. The financial results will be released after market close on the same day. CEO Miguel Martin and CFO Glen Ibbott will lead the call, which will include a question and answer session. Aurora is recognized as a global leader in the cannabis industry, providing innovative products across medical and consumer markets.
Aurora Cannabis (NYSE: ACB) announced the filing of a new preliminary short form base shelf prospectus, allowing for the qualification of various securities up to $1 billion over a 25-month period. The prospectus will enable the company to pursue strategic initiatives, including acquisitions and partnerships, as part of its global growth strategy. This filing is aimed at maximizing flexibility for shareholder value enhancement. Aurora continues to be a leader in the cannabis industry, catering to both medical and consumer markets.
Aurora Cannabis reported a net revenue of $70.3 million for Q2 2021, an 11% increase year-over-year, primarily driven by a 42% growth in medical cannabis sales. Notably, international medical sales surged 562%. The adjusted EBITDA loss improved by $53.1 million to $12.1 million, despite ongoing restructuring costs. Cash burn reduced by 74%, with cash on hand at $565 million. The company anticipates future cash flow improvement with its cost management strategies.
Aurora Cannabis Inc. (NYSE: ACB, TSX: ACB) has announced a conference call scheduled for February 11, 2021, at 5:00 p.m. Eastern Time to discuss its financial results for the fiscal year 2021 second quarter, ending December 31, 2020. CEO Miguel Martin and CFO Glen Ibbott will host the call. Results will be released following market close on the same day. Aurora is recognized as a leading player in the cannabis industry, focusing on high-quality products for medical and recreational markets.
Aurora Cannabis Inc. has announced a five-year strategic supply agreement with MedReleaf Australia, making MedReleaf the exclusive supplier of Aurora's brands in Australia. The partnership covers EUGMP-certified products, including dried flower, oils, and soft gels, without requiring capital investment from Aurora. With Aurora holding a 10% stake in MedReleaf, this move aims to enhance the availability of high-quality medical cannabis for patients in Australia. Both companies are committed to expanding their reach in the rapidly growing Australian medical cannabis market.
Aurora Cannabis Inc. (NYSE: ACB) announced the closing of its bought deal public offering, raising US$137,940,000 by selling 13,200,000 Units at US$10.45 each. This includes 1,200,000 Units from the over-allotment option. Each Unit consists of one common share and half a warrant, with each full warrant allowing the purchase of one common share at US$12.60 for 36 months. Proceeds will be used for general corporate purposes, including debt reduction, aligning with the company's strategy for a strong balance sheet.
Aurora Cannabis has successfully closed its public offering of units, generating US$137,940,000. A total of 13,200,000 units were sold at US$10.45 each, including 1,200,000 units from an over-allotment option. Each unit consists of one common share and a warrant, exercisable at US$12.60 for three years. The proceeds will be used for general corporate purposes, including potential debt reduction. BMO Capital Markets and ATB Capital Markets were the bookrunners for this offering.
Aurora Cannabis has announced a bought deal offering of 12 million units at US$10.45 each, raising approximately US$125 million, led by BMO Capital Markets and ATB Capital Markets. Each unit consists of one common share and half a warrant, with warrants exercisable for three years at US$12.60. The offering, expected to close by January 26, 2021, will help support general corporate purposes and potentially reduce debt. The prospectus will be filed in Canada and the U.S.
FAQ
What is the current stock price of Aurora Cannabis Common Shares (ACB)?
What is the market cap of Aurora Cannabis Common Shares (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
